ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

HLX319

A development code.

Its studies are mostly in Breast Neoplasms, led by Fosun Pharma.

Furthest: phase 1, since Mar 22, 20262 company-led studies, 2 open or runningNext primary completion: Apr 23, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Fosun Pharma22 open or runningphase 1since Mar 22, 2026Mar 22, 2026Apr 23, 2027phase 1 · NCT07601620

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 22, 2026First study: phase 1 study in Health Adult SubjectsFirst studyNCT07495930 · 24 planned · China
  2. May 8, 2026Phase 1 study in Breast NeoplasmsNCT07601620 · 258 planned

Ahead

  1. Apr 23, 2027Primary completion: phase 1 study in Breast NeoplasmsNCT07601620

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07601620Breast Neoplasms1Not yet recruitingApr 23, 2027258
NCT07495930Health Adult Subjects · China1Not yet recruitingJul 1, 202624

How it is read

Names in the registry

  • “HLX319”, 2 entries

Codes read as this program: HLX319.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.